BEIJING, Feb. 08, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to conduct clinical trials of ICP-538, a VAV1-directed molecular glue degrader (MGD). This is the first VAV1 degrader approved to enter clinical trials in China and the second globally. Read More
Source link
Watch highlights from the 2026 Super Bowl
IE 11 is not supported. For an optimal experience visit our site on another browser. Now Playing Watch highlights from the 2026 Super Bowl 02:05 UP NEXT Spectators gather in…








